SEC Filing Summary: Zapata Corporation (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1999, for Zapata Corporation. The Company changed its fiscal year-end from September 30 to December 31, effective January 1, 1999. Zapata primarily holds a 61% interest in Omega Protein Corporation (marine protein products) and a 40% interest in Viskase Companies, Inc. (food packaging). It also operates internet properties including ZAP.COM. The financial statements are unaudited.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 1999 |
Three Months Ended June 30, 1998 |
Six Months Ended June 30, 1999 |
Six Months Ended June 30, 1998 |
|---|---|---|---|---|
| Revenues | $18,225 | $31,488 | $40,387 | $61,529 |
| Operating Income (Loss) | $(2,952) | $9,242 | $(321) | $18,421 |
| Net Income (Loss) | $(885) | $58,140 | $(1,496) | $64,610 |
| Diluted EPS | $(0.04) | $2.40 | $(0.06) | $2.67 |
| Cash and Equivalents | $136,939 | $154,704 | $136,939 | $159,253 |
| Total Debt (Current + Long-term) | $11,697 | $12,238 | $11,697 | $12,238 |
| Working Capital | $187,279 | $194,148 | $187,279 | $194,148 |
Note: 1998 figures include a one-time $86.7 million gain from the sale of Omega Protein stock.
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped 42.2% in the quarter and 34.3% in the six-month period compared to 1998. This was driven by a 21.2% to 45.3% decline in selling prices for fish meal and fish oil, and a strategic decision by Omega Protein to defer sales due to unfavorable market conditions.
- Profitability Shift: The Company moved from significant net income in 1998 to a net loss in 1999. The 1998 results were heavily skewed by the $86.7 million gain on the Omega Protein IPO. Excluding this gain, operating performance deteriorated due to lower margins and increased costs.
- Cash Flow: Net cash used by operating activities increased to $4.4 million for the six months ended June 30, 1999, compared to $2.7 million in the prior year, primarily due to inventory build-up at Omega Protein.
- Viskase Investment: Zapata suspended recording equity losses from its 40% stake in Viskase after the investment was reduced to zero due to Viskase's massive restructuring charges in late 1998.
Outlook, Risks, and Contingencies
- ZAP.COM Rights Offering: Zapata is pursuing a rights offering for its subsidiary ZAP.COM to raise up to $108.9 million. Zapata plans to invest $8 million in ZAP.COM. Completion is expected in the third or fourth quarter of 1999, but is not guaranteed.
- Legal Proceedings:
- Employee Litigation: A $3.45 million judgment was entered against Zapata regarding stock options for a former employee. Zapata has appealed and posted a bond.
- Securities Class Action: Consolidated lawsuits allege false statements regarding internet acquisitions. Zapata intends to defend vigorously.
- Settlements: The "Holt Case" was settled with no material adverse effect; the "Harwin/Crandon Case" was dismissed without prejudice.
- Year 2000 (Y2K): Zapata and Omega Protein are assessing Y2K compliance. Zapata expects minimal costs, while Omega Protein is surveying major vendors and customers. No contingency plans are currently finalized.
- Liquidity: Management believes existing cash ($136.9 million) is sufficient to meet requirements through the end of 2000, pending the ZAP.COM offering.
Investor Verification Checklist
- Market Pricing: Verify current commodity prices for menhaden fish meal and oil to assess the sustainability of Omega Protein's revenue recovery.
- ZAP.COM Offering Status: Confirm if the ZAP.COM rights offering has been declared effective and the actual capital raised, as this impacts future cash flow and ownership dilution.
- Legal Outcomes: Monitor the appeal status of the $3.45 million employee judgment and the progress of the securities class action litigation.
- Viskase Recovery: Track Viskase's financial performance to determine when Zapata might resume recognizing equity earnings or losses from this affiliate.
- Inventory Levels: Review Omega Protein's inventory valuation, as the build-up of high-cost inventory is currently pressuring margins.